Neutrophilic Asthma and Potentially Related Target Therapies
| Autor: | Pranav Nair, Kedar S. Prabhavalkar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Neutrophils
Clinical Biochemistry Drug Resistance Inflammation 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Drug Discovery Neutrophilic asthma medicine Humans Anti-Asthmatic Agents Target therapy Adverse effect Asthma Pharmacology Inhalation business.industry medicine.disease respiratory tract diseases Clinical trial Corticosteroid insensitivity Phenotype 030220 oncology & carcinogenesis Immunology Cytokines Molecular Medicine medicine.symptom business |
| Zdroj: | Current Drug Targets. 21:374-388 |
| ISSN: | 1389-4501 |
| DOI: | 10.2174/1389450120666191011162526 |
| Popis: | Background: Neutrophilic asthma is generally associated with the absence of eosinophils and activation of non- predominant type 2 immunological pathways. It involves bronchial inflammation followed by different degrees of airway remodeling. Neutrophilic inflammation activates specific cellular and molecular pathways due to inhalation of environmental trigger factors such as exhaust fumes, cigarette smoke, occupation-related agents, and infections. Objective: This review discusses the involvement of neutrophils in asthma and potentially related target therapies. Results: Corticosteroid resistance is the hallmark of neutrophilic asthma which increases disease severity and leads to difficult-to-control asthma. Patients with neutrophil-dominant asthma are characterized by low levels of (or absence of) Th2 cytokines. Due to the shortage of effective treatments for neutrophilic asthma newer biologics are being developed that target type 2 asthma symptoms and phenotypes. Understanding different biomarkers, inflammatory pathways and treatment strategies involved in neutrophilic asthma will help to decrease adverse effects related to corticosteroid insensitivity. Better insight of targets involved in neutrophilic inflammation can lead to improved therapies. Conclusion: Further evaluation and clinical trials of emerging biologics involved in neutrophilic asthma needs to be performed before bringing them into clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|